Cargando…
A Light-Driven Therapy of Pancreatic Adenocarcinoma Using Gold Nanorods-Based Nanocarriers for Co-Delivery of Doxorubicin and siRNA
In this work, we report the engineering of polyelectrolyte polymers coated Gold nanorods (AuNRs)-based nanocarriers that are capable of co-delivering small interfering RNA (siRNA) and an anticancer drug doxorubicin (DOX) to Panc-1 cancer cells for combination of both chemo- and siRNA-mediated mutant...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4440440/ https://www.ncbi.nlm.nih.gov/pubmed/26000055 http://dx.doi.org/10.7150/thno.11335 |
_version_ | 1782372640297582592 |
---|---|
author | Yin, Feng Yang, Chengbin Wang, Qianqian Zeng, Shuwen Hu, Rui Lin, Guimiao Tian, Jinglin Hu, Siyi Lan, Rong Feng Yoon, Ho Sup Lu, Fei Wang, Kuan Yong, Ken-Tye |
author_facet | Yin, Feng Yang, Chengbin Wang, Qianqian Zeng, Shuwen Hu, Rui Lin, Guimiao Tian, Jinglin Hu, Siyi Lan, Rong Feng Yoon, Ho Sup Lu, Fei Wang, Kuan Yong, Ken-Tye |
author_sort | Yin, Feng |
collection | PubMed |
description | In this work, we report the engineering of polyelectrolyte polymers coated Gold nanorods (AuNRs)-based nanocarriers that are capable of co-delivering small interfering RNA (siRNA) and an anticancer drug doxorubicin (DOX) to Panc-1 cancer cells for combination of both chemo- and siRNA-mediated mutant K-Ras gene silencing therapy. Superior anticancer efficacy was observed through synergistic combination of promoted siRNA and DOX release upon irradiating the nanoplex formulation with 665 nm light. Our antitumor study shows that the synergistic effect of AuNRs nanoplex formulation with 665 nm light treatment is able to inhibit the in vivo tumor volume growth rate by 90%. The antitumor effect is contributed from the inactivation of K-Ras gene and thereby causing a profound synthesis (S) phase arrest in treated Panc-1 cells. Our study shows that the percentage of Panc-1 cells treated by nanoplex formulation with S phase is determined to be 35% and it is 17% much higher than that of Panc-1 cells without any treatments. The developed nanotherapy formulation here, that combines chemotherapy, RNA silencing and NIR window light-mediated therapy, will be seen to be the next natural step to be taken in the clinical research for improving the therapeutic outcomes of the pancreatic adenocarcinoma treatment. |
format | Online Article Text |
id | pubmed-4440440 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-44404402015-05-21 A Light-Driven Therapy of Pancreatic Adenocarcinoma Using Gold Nanorods-Based Nanocarriers for Co-Delivery of Doxorubicin and siRNA Yin, Feng Yang, Chengbin Wang, Qianqian Zeng, Shuwen Hu, Rui Lin, Guimiao Tian, Jinglin Hu, Siyi Lan, Rong Feng Yoon, Ho Sup Lu, Fei Wang, Kuan Yong, Ken-Tye Theranostics Research Paper In this work, we report the engineering of polyelectrolyte polymers coated Gold nanorods (AuNRs)-based nanocarriers that are capable of co-delivering small interfering RNA (siRNA) and an anticancer drug doxorubicin (DOX) to Panc-1 cancer cells for combination of both chemo- and siRNA-mediated mutant K-Ras gene silencing therapy. Superior anticancer efficacy was observed through synergistic combination of promoted siRNA and DOX release upon irradiating the nanoplex formulation with 665 nm light. Our antitumor study shows that the synergistic effect of AuNRs nanoplex formulation with 665 nm light treatment is able to inhibit the in vivo tumor volume growth rate by 90%. The antitumor effect is contributed from the inactivation of K-Ras gene and thereby causing a profound synthesis (S) phase arrest in treated Panc-1 cells. Our study shows that the percentage of Panc-1 cells treated by nanoplex formulation with S phase is determined to be 35% and it is 17% much higher than that of Panc-1 cells without any treatments. The developed nanotherapy formulation here, that combines chemotherapy, RNA silencing and NIR window light-mediated therapy, will be seen to be the next natural step to be taken in the clinical research for improving the therapeutic outcomes of the pancreatic adenocarcinoma treatment. Ivyspring International Publisher 2015-04-20 /pmc/articles/PMC4440440/ /pubmed/26000055 http://dx.doi.org/10.7150/thno.11335 Text en © 2015 Ivyspring International Publisher. Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. See http://ivyspring.com/terms for terms and conditions. |
spellingShingle | Research Paper Yin, Feng Yang, Chengbin Wang, Qianqian Zeng, Shuwen Hu, Rui Lin, Guimiao Tian, Jinglin Hu, Siyi Lan, Rong Feng Yoon, Ho Sup Lu, Fei Wang, Kuan Yong, Ken-Tye A Light-Driven Therapy of Pancreatic Adenocarcinoma Using Gold Nanorods-Based Nanocarriers for Co-Delivery of Doxorubicin and siRNA |
title | A Light-Driven Therapy of Pancreatic Adenocarcinoma Using Gold Nanorods-Based Nanocarriers for Co-Delivery of Doxorubicin and siRNA |
title_full | A Light-Driven Therapy of Pancreatic Adenocarcinoma Using Gold Nanorods-Based Nanocarriers for Co-Delivery of Doxorubicin and siRNA |
title_fullStr | A Light-Driven Therapy of Pancreatic Adenocarcinoma Using Gold Nanorods-Based Nanocarriers for Co-Delivery of Doxorubicin and siRNA |
title_full_unstemmed | A Light-Driven Therapy of Pancreatic Adenocarcinoma Using Gold Nanorods-Based Nanocarriers for Co-Delivery of Doxorubicin and siRNA |
title_short | A Light-Driven Therapy of Pancreatic Adenocarcinoma Using Gold Nanorods-Based Nanocarriers for Co-Delivery of Doxorubicin and siRNA |
title_sort | light-driven therapy of pancreatic adenocarcinoma using gold nanorods-based nanocarriers for co-delivery of doxorubicin and sirna |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4440440/ https://www.ncbi.nlm.nih.gov/pubmed/26000055 http://dx.doi.org/10.7150/thno.11335 |
work_keys_str_mv | AT yinfeng alightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna AT yangchengbin alightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna AT wangqianqian alightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna AT zengshuwen alightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna AT hurui alightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna AT linguimiao alightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna AT tianjinglin alightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna AT husiyi alightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna AT lanrongfeng alightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna AT yoonhosup alightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna AT lufei alightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna AT wangkuan alightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna AT yongkentye alightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna AT yinfeng lightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna AT yangchengbin lightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna AT wangqianqian lightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna AT zengshuwen lightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna AT hurui lightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna AT linguimiao lightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna AT tianjinglin lightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna AT husiyi lightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna AT lanrongfeng lightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna AT yoonhosup lightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna AT lufei lightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna AT wangkuan lightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna AT yongkentye lightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna |